Alum-Adsorbed Native Subcutaneous Immunotherapy Product
Alutek is a European-developed alum-adsorbed native subcutaneous immunotherapy (SCIT) product designed to treat environmental allergies such as dust mites and grass pollens. As a native extract, it retains full allergen potency, offering the potential for strong immune responses and higher desensitisation ceilings compared with allergoid formulations.
Overview
Alutek is administered in clinic under strict protocols, including build-up and maintenance phases, providing controlled and monitored desensitisation for patients with confirmed IgE-mediated allergies.
Safety Profile
As a native extract, Alutek carries a higher risk of local and systemic allergic reactions than allergoid products. Common side effects include:
Common side effects include:
Mild local swelling or redness at the injection site
Temporary itching or discomfort
Rare systemic reactions, managed with standard emergency procedures in the clinic
Effectiveness
Clinical experience indicates that Alutek can provide strong and sustained symptom reduction for environmental allergies.
Improvements generally become noticeable over months, with maximum benefit typically achieved over a 3–5 year course of regular SCIT.
3–5 year treatment course
Treatment options
Single allergen therapy
Single allergen therapy:
Targeted desensitisation to a specific allergen such as dust mites or grass pollen.
Multi-allergen therapy
Multi-allergen therapy:
Possible, but careful clinician planning is required due to higher systemic reaction risk.
Both TGA-registered and non-registered options exist.
Clinics must inform patients that all options are privately funded in Australia, with total treatment costs varying from several hundred to several thousand dollars per year.
Administered via subcutaneous injection in clinic
Initial build-up phase with gradual dose increases
Maintenance phase involves less frequent injections for sustained desensitisation
Requires patient monitoring for potential adverse reactions
Patient Suitability
Have confirmed IgE-mediated allergies to environmental allergens
Seek maximal potential desensitisation
Can tolerate clinic-based injections
Are informed about higher risk profile compared with allergoids
Australian Context
Not PBS-subsidised; treatment is privately funded
Conclusion
Alutek offers a high-potency native SCIT option for patients seeking maximum desensitisation to environmental allergens.
While the risk of systemic reactions is higher, careful clinic-based management allows patients to achieve potentially superior long-term outcomes.
